Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

EMA’s CHMP Recommends Approval of Eight New Medicines

  • Post author:PacConAdmin
  • Post published:February 26, 2023
  • Post category:Drug Industry Daily

The European Medicines Agency’s (EMA) human medicines committee has endorsed eight new drugs for approval following its February monthly meeting. Source: Drug Industry Daily

Continue ReadingEMA’s CHMP Recommends Approval of Eight New Medicines

FDA Raps API Facility in Nebraska for Microbial Contamination

  • Post author:PacConAdmin
  • Post published:February 26, 2023
  • Post category:Drug Industry Daily

ALI Pharmaceutical, a drug intermediate and active pharmaceutical ingredient (API) manufacturer in Omaha, Neb., was hit with a Form 483 for microbial contamination of products, failure to establish microbiological specifications…

Continue ReadingFDA Raps API Facility in Nebraska for Microbial Contamination

Researchers Urge FDA to Quickly Withdraw Accelerated Approvals After Negative Trial Data

  • Post author:PacConAdmin
  • Post published:February 26, 2023
  • Post category:Drug Industry Daily

The FDA should move more quickly to withdraw its approval of drugs granted Accelerated Approval (AA) when negative confirmatory trial data emerge, said members of a research team that studied…

Continue ReadingResearchers Urge FDA to Quickly Withdraw Accelerated Approvals After Negative Trial Data

Gene Therapy Consortium to Launch Pilot for Rare Diseases, Says CBER’s Marks

  • Post author:PacConAdmin
  • Post published:February 26, 2023
  • Post category:Drug Industry Daily

The FDA will soon announce a new pilot program to help developers of gene therapies for rare diseases get their treatments approved faster, said Peter Marks, director of the FDA’s…

Continue ReadingGene Therapy Consortium to Launch Pilot for Rare Diseases, Says CBER’s Marks

BioMarin’s Hemophilia Gene Therapy Improves Bleeding Rates for Two Years

  • Post author:PacConAdmin
  • Post published:February 26, 2023
  • Post category:Drug Industry Daily

A single infusion of BioMarin’s Roctavian (valoctocogene roxaparvovec) reduced bleeding rates by 84 percent for two years in patients with hemophilia A, according to a study published in The New…

Continue ReadingBioMarin’s Hemophilia Gene Therapy Improves Bleeding Rates for Two Years

Coalition of States Sues FDA Over Abortion Pill REMS

  • Post author:PacConAdmin
  • Post published:February 26, 2023
  • Post category:Drug Industry Daily

Attorneys general from a dozen states have filed a lawsuit against the FDA over its Risk Evaluation and Mitigation Strategies (REMS) for the abortion pill, mifepristone, arguing that the restrictions are…

Continue ReadingCoalition of States Sues FDA Over Abortion Pill REMS

AstraZeneca Expands Gastric Cancer Reach With KYM Biosciences’ ADC Candidate

  • Post author:PacConAdmin
  • Post published:February 22, 2023
  • Post category:Drug Industry Daily

AstraZeneca has announced plans to extend its oncology drug portfolio through a licensing deal with KYM Biosciences for an investigational antibody-drug conjugate (ADC) for treatment of gastric cancer. Source: Drug…

Continue ReadingAstraZeneca Expands Gastric Cancer Reach With KYM Biosciences’ ADC Candidate

CMS Signals It’s Open to Negotiation on Antiamyloid Antibody Coverage

  • Post author:PacConAdmin
  • Post published:February 22, 2023
  • Post category:Drug Industry Daily

In another Alzheimer’s disease therapeutics payment slapdown, the Centers for Medicare and Medicaid Services (CMS) rejected a petition by the Alzheimer’s Association to expand coverage of antiamyloid antibody therapy, but…

Continue ReadingCMS Signals It’s Open to Negotiation on Antiamyloid Antibody Coverage

Icosavax Gains Fast Track for Innovative Vaccine

  • Post author:PacConAdmin
  • Post published:February 22, 2023
  • Post category:Drug Industry Daily

The FDA has granted Fast Track designation to Icosavax’s IVX-A12, an innovative investigational bivalent vaccine that targets both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Source: Drug Industry Daily

Continue ReadingIcosavax Gains Fast Track for Innovative Vaccine

Lawmakers Warn Patent Office of Keytruda Patent Abuse

  • Post author:PacConAdmin
  • Post published:February 22, 2023
  • Post category:Drug Industry Daily

Senators Elizabeth Warren (D-Mass.) and Bernie Sanders (I-Vt.) want Merck to slow down its Keytruda patent juggernaut. Source: Drug Industry Daily

Continue ReadingLawmakers Warn Patent Office of Keytruda Patent Abuse
  • Go to the previous page
  • 1
  • …
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.